The cytochrome b5 tail anchors and stabilizes subdomains of human DNA topoisomerase IIα in the cytoplasm of retrovirally infected mammalian cells

Experimental Cell Research

Volumn 249, Issue 2, 1999, Pages 308-319

  Soltermann, Alex ^a   Ernst, Angelika ^b   Leroy, Didier ^a   Stahel, Rolf A ^b   Gasser, Susan M ^a  

^a SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cytochrome b5; Cytoplasmic anchoring; DNA topoisomerase II; Etoposide; Multiple drug resistance; Retroviral gene expression

Indexed keywords

CYTOCHROME B5; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; ETOPOSIDE; FLAG PEPTIDE; HYBRID PROTEIN; ISOENZYME; OLIGOPEPTIDE; PEPTIDE; PEPTIDE FRAGMENT; TUMOR ANTIGEN;

ANIMAL CELL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; HUMAN; MAMMAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RETROVIRUS INFECTION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL LINE; DRUG EFFECT; ENZYMOLOGY; GENE TRANSFER; GENETICS; METABOLISM; MOUSE; NUCLEAR LOCALIZATION SIGNAL; PHYSIOLOGY; RAT; RETROVIRUS; VIROLOGY;

ANIMALIA; MAMMALIA; RODENTIA; UNIDENTIFIED RETROVIRUS;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE; CYTOCHROMES B5; CYTOPLASM; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ETOPOSIDE; GENE TRANSFER TECHNIQUES; HUMANS; ISOENZYMES; MICE; NUCLEAR LOCALIZATION SIGNALS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; TUMOR CELLS, CULTURED;

EID: 0033563317     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4446     Document Type: Article

References (45)

1. Wang J. C. DNA topoisomerases. Annu. Rev. Biochem. 65:1996;635-692.
2. Watt P. M., Hickson I. D. Structure and function of type II DNA topoisomerases. Biochem. J. 303:1994;681-695.
3. Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:1989;351-375.
4. Nitiss J. L., Beck W. T. Antitopoisomerase drug action and resistance. Eur. J. Cancer. 32:1996;958-966.
5. Borst P., Schinkel A. H. Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet. 13:1997;217-222.
6. Deeley R. G., Cole S. P. C. Function, evolution and structure of multidrug resistance protein (MRP). Semin. Cancer Biol. 8:1997;193-204.
7. Corbett A. H., Osheroff N. When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol. 6:1993;585-597.
8. Vassetzky Y. S., Alghisi G. C., Gasser S. M. DNA topoisomerase II mutations and resistance to anti-tumor drugs. BioEssays. 17:1995;767-774.
9. Vassetzky Y. S., Alghisi G. C., Roberts E., Gasser S. M. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumor drug, etoposide. Br. J. Cancer. 73:1996;1201-1209.
10. Feldhoff P. W., Mirski S. E. L., Cole S. P. C., Sullivan D. M. Altered subcellular distribution of topoisomerase IIα in drug-resistant human small cell lung cancer cell line. Cancer Res. 54:1994;756-762.
11. Harker G. W., Slade D. L., Parr R. L., Holguin M. H. Selective use of an alternative stop codon and polyadenylation signal within intron sequences in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res. 55:1995;4962-4971.
12. Mo Y. Y., Beck W. T. Heterogenous expression of DNA topoisomerase IIα isoforms in tumor cell lines. Oncol. Res. 9:1997;193-204.
13. 5 mRNA. Biochem. Biophys. Res. Commun. 156:1988;576-580.
14. Morgenstern J. P., Land H. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:1990;3587-3596.
15. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
16. Tang B. L., Tan A. E. H., Lim L. K., Lee S. S., Low D. Y. H., Hong W. Syntaxin 12, a member of the syntaxin family localized to the endosome. J. Biol. Chem. 273:1998;6944-6950.
17. Wigley D. B., Gideon J. D., Dodson E. J., Maxwell A., Dodson G. Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature. 351:1991;624-629.
18. Jensen S., Andersen A. H., Kjeldsen E., Biersack H., Olsen E. H. N., Andersen T. B., Westergaard O., Jakobsen B. K. Analysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiae. Mol. Cell. Biol. 16:1996;3866-3877.
19. Berger J. M., Gamblin S. J., Harrison S. C., Wang J. C. Structure and mechanism of DNA topoisomerase II. Nature. 379:1996;225-232.
20. 5 spans the bilayer of the endoplasmic reticulum. J. Biol. Chem. 270:1995;3414-3422.
21. Helenius A., Trombetta E. S., Hebert D. N., Simons J. F. Calnexin, calreticulin and the folding of glycoproteins. Trends Cell Biol. 7:1997;193-200.
22. 5 are necessary for its targeting to the endoplasmic reticulum. EMBO J. 11:1992;4197-4203.
23. Mirski S. E. L., Gerlach J. H., Cummings H. J., Zirngibl R., Greer P. A., Cole S. P. C. Bipartite nuclear localization signals in the C-terminus of human topoisomerase IIα Exp. Cell Res. 237:1997;452-455.
24. Cowell I. G., Willmore E., Chalton D., Marsh K. L., Jazrawi E., Fisher L. M., Austin C. A. Nuclear distribution of human DNA topoisomerase IIβ: A nuclear targeting signal resides in the 116-residue C-terminal tail. Exp. Cell Res. 243:1998;232-240.
25. Meyer K. N., Kjeldsen E., Straub T., Knudsen B. R., Hickson I. D., Kikuchi A., Kreipe H., Boege F. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J. Cell Biol. 136:1997;775-788.
26. Swedlow J. R., Sedat J. W., Agard D. A. Multiple chromosomal populations of topoisomerase II detected in vivo by time-lapse, three-dimensional wide-field microscopy. Cell. 73:1993;97-108.
27. Austin C. A., Marsh K. L. Eukaryotic DNA topoisomerase IIβ BioEssays. 20:1998;215-226.
28. Nakajima T., Morita K., Ohi N., Arai T., Nozaki N., Kikuchi A., Osaka F., Yamao F., Oda K. Degradation of topoisomerase IIα during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. J. Biol. Chem. 271:1996;24842-24849.
29. Ossovskaya V. S., Mazo I. A., Chernov M. V., Chernova O. B., Strezoska Z., Kondratov R., Stark G. R., Chumakov P. M., Gudkov A. V. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc. Natl. Acad. Sci. USA. 93:1996;10309-10314.
30. Gudkov A. V., Zelnick C. R., Kazarov A. R., Thimmapaya R., Suttle D. P., Beck W. T., Roninson I. B. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc. Natl. Acad. Sci. USA. 90:1993;3231-3235.
31. Adachi N., Miyaike M., Kato S., Kanamaru R., Koyama H., Kikuchi A. Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain. Nucleic Acids Res. 25:1997;3135-3142.
32. McPherson J. P., Goldenberg G. J. Induction of apoptosis by deregulated expression of DNA topoisomerase IIα Cancer Res. 58:1998;4519-4524.
33. Glotzer M., Murray A. W., Kirschner M. W. Cyclin is degraded by the ubiquitin pathway. Nature. 349:1991;132-138.
34. 5 gene. Biochem. Biophys. Res. Commun. 209:1995;894-900.
35. 5 with lengthened membrane anchor escapes from the endoplasmic reticulum and reaches the plasma membrane. Proc. Natl. Acad. Sci. USA. 93:1996;4207-4212.
36. 5. The problem of posttranslational targeting to the endoplasmic reticulum. Borgese N., Harris J. R. Subcellular Biochemistry. 1993;313-341 Plenum, New York.
37. Hunt T. Cytoplasmic anchoring proteins and the control of nuclear localization. Cell. 59:1989;949-951.
38. Dingwall C., Laskey R. A. Nuclear targeting sequences - A consensus. Trends Biochem. Sci. 16:1991;478-481.
39. 1492 in the COOH-terminal region of topoisomerase IIα in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res. 57:1997;4451-4454.
40. Mirski S. E. L., Evans C. D., Almquist K. C., Slovak M. L., Cole S. P. C. Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res. 53:1993;4866-4873.
41. Campling B. G., Baer K. A., Gerlach J. H., Lam Y. M., Cole S. P. C., Mirski S. E. L. Topoisomerase II levels and drug response in small cell lung cancer. Int. J. Oncol. 10:1997;885-893.
42. Gallagher R., Collins S., Trujillo J., McCredie K., Ahearn M., Tsai S., Metzgar R., Aulakh G., Ting R., Ruscetti F., Gallo R. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 54:1979;713-733.
43. Harker W. G., Slade D. L., Dalton W. S., Meltzer P. S., Trent J. M. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49:1989;4542-4549.
44. Foley G. E., Lazarus H., Farber S., Uzman B. G., Boone B. A., McCarthy R. E. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer. 18:1965;522-529.
45. Mirski S. E. L., Cole S. P. C. Cytoplasmic localization of a mutant Mr 160,000 topoisomerase IIα is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res. 55:1995;2129-2134.